129 results about "Prolonged-release tablet" patented technology

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

The present invention discloses a tofacitinib citrate sustained-release tablet preparation and a preparation method thereof, which belongs to the technical field of pharmaceutical preparations. The sustained-release tablet comprises a double-layer core and a coating layer; the double-layer core comprises a drug-containing layer and a push layer; wherein the drug-containing layer comprises: tofacitinib citrate, an adhesive, polyethylene oxide, a glidant and a lubricant; the push layer comprises: mannitol, an adhesive, red iron oxide, polyethylene oxide, a glidant and a lubricant; the coating layer comprises: cellulose acetate, a pore-forming agent, a plasticizer, water and acetone. The sustained-release tablet preparation of the present invention solves the technical problems existing in the prior art by adopting a double-layer osmotic pump prescription design, adopting non-hygroscopic materials such as mannitol, adopting a standard round tablet design, preparing a sustained-release coating layer without using methanol, and adopting a coating machine for coating and curing.

The gastric retention type sustained-release tablet comprises a blank retention layer and a drug-loaded sustained-release layer which are arranged on the surface layer of a plain tablet of the gastric retention type sustained-release tablet, the blank retention layer is prepared from the following raw materials: a skeleton type slow-release material, a floating aid and an expanding agent; the medicine-carrying sustained-release layer is prepared from the following raw materials: a skeleton type sustained-release material, a floating aid and an active medicine component. According to the invention, calcium silicate with low bulk density and super absorbent resin are respectively used as a floating aid and an expanding agent, so that the gastric retention type sustained-release tablet has similar gastric retention capability with a common single-layer tablet, and has a very good sustained-release effect at the same time; through the arrangement of the blank retention layer and the drug-loaded sustained-release layer, the sustained release of drugs with low solubility in acid can also be realized in the form of gastric retention type sustained-release tablets.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The application discloses a salbutamol sulfate sustained-release tablet and a preparation process thereof. The preparation process comprises the following steps: drug micronization treatment, drug and ion exchange resin compounding, granulation with hydrophilic gel matrix material, gradient temperature control drying, total mixing after whole granulation, tabletting, double controlled-release coating, ladder solidification treatment and screening and packaging. Through the synergistic sustained-release effect of the ion exchange resin and the hydrophilic gel matrix material, the double controlled-release coating and the ladder solidification process, the application effectively inhibits drug burst release, realizes smooth and long-lasting release, reduces impurity content, and improves product stability and batch reproducibility. The obtained sustained-release tablet releases 20%-40% in 2 hours and 80% or more in 8 hours in a pH 6.8 phosphate buffer, and the quality is controllable, so the sustained-release tablet is suitable for industrial production.

The utility model discloses a tablet press feed hopper for sustained release tablet production, which relates to the technical field of sustained release tablet production and comprises a feed hopper, a mounting seat is arranged at the bottom of the feed hopper, a connecting top cover is arranged at the top of the feed hopper, a connecting sleeve is arranged at the bottom of the connecting top cover, and a positioning bolt is arranged outside the connecting sleeve. An anti-blocking assembly is arranged on the top of the connecting top cover, a pulling handle is installed on one side of the top of the connecting top cover, and the pulling handle and the anti-blocking assembly are arranged adjacently. Raw materials accumulated in the feeding hopper are conveyed through the arranged anti-blocking assembly, the rotating rod and the spiral conveying paddle are driven by the arranged driving motor to rotate, so that the raw materials are conveyed, and meanwhile the raw materials are prevented from being accumulated in the feeding hopper, blocking is caused, and the discharging efficiency is affected; the spiral conveying paddle is used in cooperation with the cleaning scraping plate, and the raw material station is prevented from adhering to the inner wall of the feeding hopper.

This application relates to the field of pharmaceutical equipment technology, and discloses an apparatus and method for granulating sustained-release drugs, to solve the problem of rapid drug release from sustained-release tablets due to short compression time and lack of compaction. A granulation structure is fixedly installed inside a housing. The granulation structure includes a fixed plate, a support shaft, a rotating gear, and a granulation belt. The granulation belt has a granulation groove, and two granulation belts are installed in a V-shape. Powdered sustained-release drug is discharged into the granulation groove. A power motor drives the support shaft, rotating gear, and granulation belt to rotate in opposite directions, causing the granulation groove to compress the powdered sustained-release drug in the granulation groove. As the granulation groove moves from the top to the bottom of the granulation belt, the compressive force on the powdered sustained-release drug increases, and the compression time of the powdered sustained-release drug in the granulation groove is extended, so that the powdered sustained-release drug is compacted, preventing breakage of the compressed sustained-release tablets.

The invention discloses a centrifugal granulation process for producing slow-release indapamide, which comprises the following steps: S1, stirring and mixing indapamide, a slow-release framework material, a lubricant and a filler; s2, putting the mixed powder into a disc of a granulation device, and performing low-speed centrifugal granulation in a vacuum state to form a mother nucleus; s3, transferring the mother nucleus to a high-pressure state for centrifugal granulation; s4, performing low-temperature drying on the granules; and S5, after drying, tabletting by using a tablet press, and finally coating and packaging by using double aluminum to obtain the indapamide sustained-release tablet. According to the invention, high and low pressure conversion is carried out in the centrifugal granulation process, so that gas in the sustained-release tablet is reduced, the density is increased synchronously, and the sustained-release capability and the efficacy durability of the tablet are improved.

The invention provides a cefditoren pivoxil sustained-release tablet which comprises cefditoren pivoxil, a crystal transformation inhibiting material, a framework material, a pore-foaming agent, an adhesive, an antioxidant and a lubricant, the crystal transformation inhibiting material, the framework material and the adhesive are all polyoxyethylene, the pore-foaming agent is polyethylene glycol 8000, the antioxidant is polyethylene glycol 8000, and the lubricant is polyethylene glycol 8000. The cefditoren pivoxil crystal form can effectively overcome the defect that an existing cefditoren pivoxil preparation is taken many times, can ensure the stability of the cefditoren pivoxil crystal form, can reduce the variety of auxiliary materials in the preparation, and is suitable for commercial production.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

The invention discloses an ingredient mixing device and method for sodium valproate sustained release tablet production, and relates to the field of pharmaceutical equipment.The ingredient mixing device comprises a mixing main body, the top of the mixing main body is connected with a top cover through a plurality of bolts, the bottom of the top cover penetrates through the bottom and is fixedly connected with a feeding cylinder, and a main shaft is arranged in the center of the interior of the mixing main body; four outer plates are fixedly connected to the outer surface of the main shaft at equal intervals, and a mixed discharging switching structure is arranged in the mixing main body. By arranging the mixing and discharging switching structure, rapid switching between a mixing mode and a discharging mode is achieved, and the structure allows a channel to be opened in the mixing stage so that materials can be subjected to sufficient convection, and allows the channel to be closed in the discharging stage so that the materials can be guided to an outlet; due to the integrated design, the tedious step that materials need to be transferred to another device for discharging after mixing in a traditional technology is avoided, the risks of procedure interruption, material loss and cross contamination are remarkably reduced, and the continuity and the overall efficiency of the production process are greatly improved.

The utility model discloses a kind of layered compression devices of multilayer sustained-release tablet, belong to pharmaceutical equipment technical field.This kind of layered compression device of multilayer sustained-release tablet, including processing table, the bottom end of processing table is equipped with support frame, the top end middle part of processing table is rotatably connected with pivot, the top end of pivot is equipped with carousel, the top end outside of carousel is equipped with several compression grooves, the inside bottom end of compression groove is equipped with ejection plate, the bottom end of pivot is through the bottom end of processing table, the bottom end of processing table is equipped with adjusting mechanism for rotating pivot, the top end of carousel is equipped with pusher mechanism, the bottom end side of processing table is equipped with first electric telescopic rod, the top end of processing table is through the output of first electric telescopic rod, the output of first electric telescopic rod and the bottom end of ejection plate are contacted, the side of processing table is equipped with stand, the side top end of stand is equipped with horizontal plate, the utility model can effectively realize automatic discharge function, improve discharging efficiency, with higher practical value.

The invention discloses a doxazosin mesylate sustained-release tablet and a preparation process thereof, and relates to the technical field of doxazosin mesylate sustained-release tablets.The sustained-release tablet comprises a double-layer tablet core composed of a first sustained-release layer and a second sustained-release layer; the double-layer tablet core is prepared from the following components in parts by mass: a first slow-release layer and a second slow-release layer; the first slow-release layer is prepared from the following components in parts by mass: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 10 to 12.5 parts of citric acid-cassava starch, 12.5 to 15 parts of magnesium aluminum silicate-cassava starch, 40 to 60 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate; the second slow-release layer is prepared from the following components in parts by weight: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 1.44 to 3.36 parts of carrageenan, 130 to 140 parts of polyethylene oxide, 30 to 40 parts of sodium alginate, 55 to 65 parts of citric acid, 67 to 77 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate.

The fragrance filter element comprises a filter element body and fragrance materials filled in the filter element body, the filter element body comprises a fragrance bottle, a filter element ring and a fairing, the filter element ring is arranged between the fragrance bottle and the fairing in a sleeved mode, the fairing is arranged on the upper portion of the fragrance bottle, and a rectification mixing cavity is formed between the inner wall of the fairing and the outer wall of the fragrance bottle. A slow release hole is formed in the top end of the fragrance bottle to communicate the rectification mixing cavity with a fragrance bottle cavity in the rectification mixing cavity, a fragrance material is placed in the fragrance bottle, and a rectification water outlet hole is formed in the rectification cover; an upper sustained-release tablet is arranged in the fragrance bottle, and an anti-overflow cavity is formed between the upper sustained-release tablet and the sustained-release hole; water enters the rectification mixing cavity from the filter element ring, the fragrance material in the fragrance bottle cavity is gradually dissolved through the slow release holes, and then the fragrance material is mixed into water and flows out through the rectification water outlet hole. The fragrance filter element is installed in the shower head in a replaceable mode, water in the shower head cannot directly enter the interior of the fragrance filter element from the bottom of the fragrance filter element to impact and dissolve the fragrance material, the fragrance material can be dissolved in the water permanently and stably, and a user can use the fragrance filter element conveniently.

The present invention relates to the field of pharmaceutical technology, and discloses fluvastatin sodium sustained-release tablets and a preparation method. The weight ratio of the raw materials of the sustained-release tablets is as follows: 25-29 parts of cellulose derivatives; 5-9 parts of polyethylene substances; 20-24 parts of fluvastatin sodium; 20-25 parts of fillers; 1-3 parts of binders; 1-1.2 parts of disintegrants; 2-3 parts of lubricants. Weigh all the raw material components according to the raw material ratio, and mix the above components evenly in sequence. Granulate the powder mixed in the previous step by dry granulation to form uniform granules. Use a fluidized bed coating device to evenly coat the coating material on the surface of the granules to form a moisture-proof and sustained-release functional coating layer. Put the coated granules into a tablet press and press them into the shape and thickness of the tablets preset by the manufacturer, and control the pressure and temperature at the same time to prepare the sustained-release tablets. Conduct quality inspection on the prepared fluvastatin sodium sustained-release tablets. Finally, perform aluminum-plastic packaging on the qualified sustained-release tablets after quality inspection and store them in a cool and dry place.

This invention relates to an utpatinib sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulation technology. The sustained-release tablet comprises a core and a coating layer. The core is formed by mixing and pressing drug-containing sustained-release particles with excipients. The drug-containing sustained-release particles are prepared by wet granulation and drying of utpatinib hemihydrate, hydroxypropyl methylcellulose, and small-particle-size microcrystalline cellulose, with the residual moisture content of the particles controlled at 1.0%–3.0% (w / w). The excipients include anhydrous citric acid, large-particle-size microcrystalline cellulose, lubricant, flow aid, and mannitol. This invention effectively solves the problems of utpatinib solubility being greatly affected by pH, unstable release, and easy tablet cracking under high hardness by constructing a synergistic system of pH adjustment and gel density, and by utilizing anhydrous citric acid to create an acidic microenvironment and enhance the strength of the HPMC gel layer, combined with the internal and external division of labor between small-particle-size and large-particle-size microcrystalline cellulose.

The invention belongs to the field of medicine cutting devices, and discloses a western medicine sustained release tablet cutting and positioning device which comprises a positioning pipe and a cutting pipe, the cutting pipe is slidably connected with a connecting shaft, the connecting shaft is connected with a connecting plate and a pressing part, the connecting plate and the inner wall of the cutting pipe are jointly connected with a second spring, the connecting plate is connected with a cutter, and the cutter is connected with a second spring. A clamping plate is rotatably connected to the inner wall of the positioning pipe, a sliding rod is connected to the inner wall of the positioning pipe, a sliding ring is slidably connected to the sliding rod, the clamping plate and the sliding ring are jointly and rotatably connected with a rotating rod, the sliding rod is sleeved with a first spring, and a medicine containing protruding block is connected to the inner wall of the positioning pipe. According to the scheme, through a flexible self-adaptive clamping and buffering segmentation structure, fragmentation is effectively prevented while tablets are segmented, immediate separation of fragments is achieved, and the accuracy and integrity of the dosage of the sustained release tablets are guaranteed.

The application discloses a quetiapine fumarate sustained-release tablet and a preparation method thereof. The sustained-release tablet is a multilayer sustained-release tablet prepared by layering and compressing after loading quetiapine fumarate in a hydrogel made of chitosan and carboxymethyl cellulose and drying. The sustained-release tablet comprises an outer layer, a middle layer and an inner layer, and the densities of the outer layer, the middle layer and the inner layer are sequentially reduced. The sustained-release tablet comprises the following components in parts by weight: quetiapine fumarate, chitosan, carboxymethyl cellulose, nano-silicon dioxide, lactose, microcrystalline cellulose and a lubricant. The components are prepared into the sustained-release tablet with excellent sustained-release effect through solution preparation, multiple cross-linking, layering and compressing and the like. The release time of the sustained-release tablet can reach 24 hours, the burst release condition at the initial stage of release is significantly reduced, the release in the first four hours is not more than 20%, the overall release effect is relatively stable, the drug absorption is facilitated, and the effect of once-a-day administration or longer time interval administration can be achieved.

The invention discloses a selenium element sustained-release tablet and a preparation method thereof, and belongs to the technical field of microelement sustained-release tablet manufacturing. The sustained release tablet is prepared from the following components in percentage by weight: 94.1 to 99.8 percent of calcium sulfate dihydrate, 0.1 to 5.0 percent of nano silicon dioxide and 0.1 to 0.9 percent of sodium selenite. The preparation method of the sustained-release tablet comprises the following steps: uniformly mixing and ball-milling calcium sulfate hemihydrate, nano silicon dioxide and sodium selenite, adding deionized water, stirring, uniformly dispersing and adsorbing selenite ions to the surfaces of calcium sulfate hemihydrate and silicon dioxide particles, injecting slurry into a mold for molding, and drying in an environment with room temperature and relative humidity of 60-90% RH after molding. The sustained release tablet prepared by the invention can slowly and stably release trace element selenium; the preparation process does not need granulation, a pressure forming process, calcination and a low-pressure high-temperature curing process; the prepared sustained release tablet is wide in application, such as a selenium-rich electric cooker, a selenium-rich pressure cooker, a selenium-rich tea cup and the like.

This application relates to the field of pharmaceutical technology and specifically discloses an upadacitinib sustained-release tablet and a method for preparing the same. Based on the solubility characteristics of upadacitinib, the present invention develops an upadacitinib sustained-release tablet with a gastric retention effect. This sustained-release tablet overcomes the drawback that drug dissolution is affected by differences in gastrointestinal pH, achieving sustained release in a low pH environment. Furthermore, the production process is simple, making it suitable for industrial production and clinical use.

The invention relates to the technical field of screening of effective components of traditional Chinese medicine compound preparations, and discloses a deep learning-based method for screening effective parts of compound mengbrand colon sustained-release tablets, which comprises the following steps of: constructing a time sequence pharmacodynamic pathway library, and recording biological pathway activity data of each component of the compound mengbrand colon sustained-release tablets at a plurality of time points; designing a causal intervention traceability network, and analyzing and quantifying the causal relationship of each component to a path node through anti-factual intervention; developing a key node identification algorithm, and identifying key regulation and control nodes; establishing a pathway evolution tracking model, and predicting the long-term influence of the drug components on the pathway; generating a mechanism interpretability score, and evaluating the pharmacodynamic mechanism reliability of each component; effective components with a definite action mechanism are screened out; according to the method, by constructing the time sequence pharmacodynamic pathway library, the complete change process of the biological pathway at multiple time points after drug intervention can be recorded, and the limitation that a traditional static end point observation method cannot track a complete causal chain is overcome.

The invention discloses a Vilciguat sustained-release tablet which comprises the following raw materials: Vilciguat particles and a sustained-release material, and the Vilciguat particles are obtained by granulating a Vilciguat aqueous solution with the pH value of 2-6 and a filler. The invention also discloses a preparation method of the Vilciguat sustained-release tablet, which comprises the following steps: uniformly mixing the raw materials of the Vilciguat sustained-release tablet, granulating, and tabletting to obtain the Vilciguat sustained-release tablet. According to the invention, through mutual cooperation of the raw materials and a specific process, the influence of intestinal environment and diet on dissolution and efficacy of the viriciguat can be avoided, the problems of repeated dissolution, precipitation and re-dissolution of the viriciguat in intestinal tracts are avoided, the dissolution effect is improved, and the viriciguat can play a more stable and longer curative effect; in addition, through mutual cooperation of the raw materials and a specific process, the Velciguat sustained release tablet has good stability.

The invention relates to a B-vitamin sports nutrition sustained release tablet and a preparation method thereof. The sustained release tablet comprises B vitamins, a lipid phase forming agent, a natural deep eutectic system glass precursor, a water activity buffer pair, ion exchange resin particles and conventional auxiliary materials, the preparation method comprises the following steps: preparing a natural deep eutectic system glass precursor, dissolving and loading the vitamin B, preparing a lipid semi-solid phase, carrying out dry mixing and wet kneading granulation, carrying out low-temperature drying granulation, carrying out final mixing, adding ion exchange resin particles subjected to standing exchange with the vitamin B and a lubricant, and tabletting. The sustained release tablet is used for sports crowds or crowds with B-group vitamin supplement requirements, and has the advantages of being strong in B-group vitamin stability protection effect in the storage and use process and capable of achieving gradual release in the gastrointestinal tract environment; the preparation method disclosed by the invention does not need a complicated microcapsule or core-shell coating process, and a slow-release effect can be realized by utilizing conventional tablet equipment.

The invention relates to the technical field of medicines, in particular to a dihydroergoline mesylate sustained-release tablet containing an antioxidant synergistic system and a preparation method of the dihydroergoline mesylate sustained-release tablet. The preparation method comprises the following steps: firstly, preparing double-molecular-weight polyethylene glycol composite microspheres as a pore-foaming agent; preparing antioxidant regulation particles, forming a buffer microenvironment by tartaric acid, citric acid monohydrate, sodium citrate and the like, and adding a water-soluble antioxidant; then preparing a fat-phase antioxidant skeleton mixture, and loading a fat-soluble antioxidant; preparing drug-containing core particles from dihydroergoline mesylate and a part of the skeleton mixture; and after mixing and tabletting, sequentially carrying out bottom layer hydrophilic film coating, middle powder layer coating and outer layer functional film coating. The sustained release tablet is stable in release within 24 hours and good in batch-to-batch consistency, oxidation impurities in acceleration and long-term stability tests are remarkably reduced, and the medication safety and the long-term effect are effectively guaranteed.

The present application relates to a kind of upatin sustained-release tablets and preparation method thereof.The present application uses mannitol, microcrystalline cellulose as filler, hydroxypropyl methyl cellulose as matrix material, malic acid as pH regulator, colloidal silicon dioxide as glidant, magnesium stearate as lubricant, after mixing raw drug with one or more excipients, dry granulation, solve the upatin preparation in the tabletting process due to the hygroscopicity of pH regulator and cause the problem of astringent, sticky and product quality change, shorten the drying time of moisture control in coating process, tablet is more stable in the process of acceleration test and influencing factor test.

The present invention relates to the technical field of pharmaceutical preparations, and specifically discloses a piribedil sustained-release tablet and a preparation method thereof. The piribedil sustained-release tablet comprises a tablet core and a coating layer, wherein the tablet core comprises piribedil, a sustained-release material, an adhesive, and a lubricant; the sustained-release material is selected from at least one of glyceryl behenate, hydrogenated oil, or talc; and the coating layer comprises a water-soluble coating material and a water-insoluble coating material. The sustained-release material is prepared into uniform hydrophobic dry granules by granulation, and then the piribedil raw material is mixed with sustained-release granules of a specific particle size so that the main drug is embedded in the gaps between the sustained-release granules, and then tableting is performed to prepare the tablet core. During the preparation process, the influence of temperature and humidity on the piribedil raw material is avoided, and the impurity stability during the preparation process is significantly improved. The dissolution curve of the prepared piribedil sustained-release tablet is similar to that of the original preparation, and the original product can be replaced.

The application discloses a coating composition of nifedipine sustained-release tablets, a preparation method and a coating process. The composition comprises HPC-L, HPC-M, polydopamine, PVP K30 and hydrophilic nanosilica, and can improve the hydration coordination of the coating layer, the film stability and the sustained-release stability.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a diclofenac sodium sustained release tablet and a preparation method thereof. The diclofenac sodium sustained-release tablet is prepared from diclofenac sodium, an ellagic acid-shellac-chitosan sustained-release material, a filling agent, a lubricating agent and an adhesive. According to the invention, a sustained-release material is prepared through solution preparation, film formation and post-treatment, and then the sustained-release tablet is prepared by adopting a wet granulation and tabletting method. Experiments show that the diclofenac sodium sustained-release tablet is good in stability, the content of diclofenac sodium basically remains unchanged after 6 months of an acceleration test, the sustained-release effect is ideal, the effective concentration maintaining time of a medicine in a body can be effectively prolonged, the medicine taking frequency is reduced, and the diclofenac sodium sustained-release tablet has good process feasibility and industrial production prospects.

This invention relates to the field of pharmaceutical technology, specifically to a sustained-release tablet of dihydroergot mesylate with composite network regulation and its preparation method. The sustained-release tablet comprises a composite structure consisting of a drug-resin composite core, an inner interface regulation structure, and an outer composite network. The key to its preparation lies in: forming a wet complex of dihydroergot mesylate with a strongly acidic cation exchange resin; sequentially introducing low-viscosity hydroxypropyl methylcellulose and a first portion of ethyl cellulose to construct the inner interface regulation layer; and after semi-drying, adding high-viscosity hydroxypropyl methylcellulose and a second portion of ethyl cellulose to form the outer composite network framework. This structure can significantly inhibit the burst release of the drug in gastric juice and achieve a stable and sustained release in intestinal juice, with stable tablet quality and good industrialization prospects.

The invention relates to the technical field of drug analysis, and discloses a method for analyzing hydrazine in a Carbidopa-levodopa sustained release tablet, which comprises the following steps: preparation of a test solution: firstly, preparing a solution required for detection, putting a Carbidopa-levodopa sustained release tablet test into an empty bottle, adding an acid solution at the moment, uniformly mixing, and then adding a sodium hydroxide solution; adding a benzaldehyde-acetonitrile solution, uniformly mixing, carrying out a derivatization reaction, after the reaction, adding n-hexane, uniformly mixing, standing for extraction, taking an n-hexane layer as a test solution, and carrying out gradient elution; according to the method, the accuracy, repeatability and matrix adaptability are verified through scientific optimized pretreatment steps of derivatization, extraction, high performance liquid chromatography parameter mobile phase and column temperature and a strict method, high-sensitivity and high-accuracy detection of the trace hydrazine in the carbidopa-levodopa sustained release tablet is achieved, meanwhile, the detection efficiency is remarkably improved, and the method is suitable for large-scale popularization and application. And a reliable technical scheme is provided for medicine quality control.